Newsletter | November 18, 2021

11.18.21 -- How Can Your Organization Overcome The Challenges Of Gene Therapy Production?

Addressing The Challenge Of Scalability In Viral Vectors

As the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. Learn how utilizing the platform’s benefits, along with our internal expertise and knowledge, provides an advantage.

Understanding The Road To Commercialization

With the current growth in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization of their therapies. Choosing a contract development manufacturing organization (CDMO) to ensure a smooth road to commercialization is essential.

Increasing The Reach Of Cell And Gene Therapies

The promise of cell and gene therapies can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. We discuss how upstream process optimization is ripe for innovative approaches.

Scaling Up Your Viral Vector Therapy

Early in the development of viral vector gene therapies, it’s critical to design a strategy that supports commercial needs based on clinical indication, patient population size, and dosing requirements. This video reveals the most important factors to consider when scaling up.

Request Information
Selecting The Right CMO For Your Gene Therapy

Getting your gene therapy to market has many challenges. Partnering with a CMO may be the quickest way to produce your therapy. Find out what criteria makes a great CMO partner and how to know if it is the right one for your gene therapy.

Request Information
Large-Scale Capabilities Facility Tour

Take a detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how the latest innovations and quality systems deliver best-in-class gene therapy services.

Request Information